Key result
Higher serum periostin in primary hyperparathyroidism independently predicts osteoporosis.
Why the study?
Periostin is an emerging biomarker involved in bone metabolism that may correlate with bone mineral density, prompting investigation of serum periostin levels and their relationship with BMD in primary hyperparathyroidism.
Are serum periostin levels elevated in patients with primary hyperparathyroidism and do they correlate with osteoporosis?
Observational (n=70)
No
Are serum periostin levels elevated in patients with primary hyperparathyroidism and do they correlate with osteoporosis?
Serum periostin levels are significantly elevated in patients with primary hyperparathyroidism and independently predict the presence of osteoporosis, suggesting its potential as a surrogate biomarker to reduce the need for DEXA imaging.
Answers are grounded in this paper and cite their sources.
Periostin may aid osteoporosis identification in primary hyperparathyroidism; hypothesis-generating and requires prospective validation.
BACKGROUND: Periostin is an emerging biomarker that plays a role in bone metabolism and may be associated with bone mineral density (BMD). This study is aimed to investigate serum periostin levels in patients with primary hyperparathyroidism (PHPT) and its correlation with BMD in these patients. METHODS: Forty patients with newly diagnosed PHPT without co-morbidities and 30 healthy controls were included. Laboratory tests for the diagnosis of PHPT and serum levels of periostin were measured for all patients. BMD was measured on lumbar spines L1 and L4 by dual-energy X-ray absorptiometry (DEXA). Serum periostin levels were detected using an enzyme-linked immunosorbent assay (ELISA). RESULTS: Serum periostin levels were significantly higher in patients with PHPT than in healthy controls (p<0.001). Serum periostin levels were also significantly higher (mean 59.7±11.0 ng/mL) in PHPT patients with osteoporosis than those without osteoporosis (p=0.004). In logistic regression analysis, only serum periostin levels independently predicted the patients with osteoporosis. According to this analysis, every 1 ng/mL increase in serum periostin increased the risk of having osteoporosis by 20.6%. When the cut-off for serum periostin level was 49.75 ng/mL, the patients with osteoporosis were predicted with 71.4% sensitivity and 69.2% specificity. Multivariate regression analysis revealed a negative correlation between serum periostin levels and L1-L4 T scores on DEXA. CONCLUSION: This is the first study to determine that serum periostin levels are higher in PHPT patients than those without PHPT and to demonstrate a significant association between serum periostin levels and T scores on DEXA in patients with PHPT. These findings will aid in detecting osteoporosis in patients with PHPT and making the decision for surgery in PHPT patients with no need for DEXA imaging that involves radiation.
No takes yet. Share an insight, caveat, or question.
Yiğitdöl et al. (2023) conducted an observational in Primary hyperparathyroidism (n=70). Primary hyperparathyroidism vs. Healthy controls was evaluated on Serum periostin levels (ng/mL) (p=<0.001). Serum periostin levels were significantly higher in patients with primary hyperparathyroidism compared to healthy controls and independently predicted the presence of osteoporosis.
Synapse has enriched 10 related papers. Consider them for comparative context: